共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
《中国神经肿瘤杂志》2011,(3):184-184
神经肿瘤杂志。2011个月;13(8):904-9。2011月13课件。海马中,steffen-smith,哈穆德,世勋,弯曲,沃伦克。小儿肿瘤科,国家癌症研究所,癌症研究中心,美国国立卫生研究院,贝塞斯达20892,医学博士,美国sean.hipp@us.army.mil 相似文献
3.
《中国神经肿瘤杂志》2009,7(2):141-141
PURPOSE: Approximately 50% of glioblastomas (GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% of instances, constitutively activated EGFR mutants are present. These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM. PATIENTS AND METHODS: In a randomized, controlled, phase Ⅱ trial, 110 patients with progressive GBM after prior radiotherapy were randomly assigned to either erlotinib or a control arm that received treatment with either temozolomide or carmusfine (BCNU). The primary end point was 6-month progression-free survival (PFS). 相似文献
4.
《中国神经肿瘤杂志》2013,(3):193-193
Glioblastoma is one of the most angiogenic human tumors and characterized by microvascular proliferations. A better understanding of glioblastoma vasculature is needed to optimize anti-angiogenic therapy that has shown a promising but incomplete efficacy. The present study examined 48 glioblastomas by CD34 endothelial marker periodic acid-Schiff (PAS) dual staining and found non-endothelial cell-lined blood vessels that were formed by tumor cells (vasculogenic mimicry, VM) existing in a fraction of these tumors. We hypothesized that CD133-positive glioblastoma stem-like ceils (GSCs) may play a pivotal role in gliohlastoma VM formation and then demonstrated in vitro and in vivo that a subset of GSCs were capable of vasculogenesis. Moreover, we found that several growth factors involved in normal angiogenesis were expressed in GSCs. We describe here a new mechanism of alternative glioblastoma vascularization and open a new perspective for the anti-vascular treatment strategy. 相似文献
5.
《中国神经肿瘤杂志》2011,(3):159+163+170+184+193+197+217
Pediatric high-grade glioma:identification of poly(ADP-ribose)polymerase as a potential therapeutic target.Neuro Oncol.2011 Aug 17.[Epub ahead of print] Smith SJ,Long A,Barrow JH,Macarthur DC,Coyle B,Grundy RG;on behalf of the Children’s Cancer and Leukaemia Group Biological Studies Committee.Children’s Brain Tumor Research Centre,University of Nottingham,Nottingham,NG7 相似文献
6.
7.
食管癌少见部位的转移临床上较少见 ,而转移灶孤立且再手术切除后长期存活则更少见 ,现将我科曾收治的一例报导如下 :患者 ,男性 ,40岁 ,进行性吞咽困难 2个月 ,于 1977年 8月收住院。查体无异常。食管钡餐造影及食管镜检查示食管癌。于入院后 10天在全麻下行食管癌根治术 ,术后恢复顺利痊愈出院。病理报告为食管鳞状细胞癌 ,中~低分化 ,侵外膜 ,食管周淋巴结转移 1/6。术后未行任何治疗。于 1990年 7月因上腭隐痛不适半月来院 ,查 :口腔内硬腭处见约 0 ,8cm× 0 .7cm溃疡 ,边缘隆起 ,中心伪膜。请口腔外科行局部切除送病理 ,并复查原… 相似文献
8.
9.
《中国神经肿瘤杂志》2009,(4)
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumorsCancer Cell. 2009 Dec 8;16(6):533-46. 相似文献
10.
《中国神经肿瘤杂志》2009,(3)
Surgical considerations for ‘intrinsic’ brainstem gliomas:proposal of a modification in classification Neurol India.2009 May-Jun;57(3):274-81.Mehta VS,Chandra PS,Singh PK,Garg A,Rath GK.Department of Neurosurgery,All India Institute of Medical Sciences,New Delhi,India.saratpchandra@gmail.com 相似文献
11.
《中国神经肿瘤杂志》2009,(1)
Occipital Transtentorial Approach and Combined Treatments for Pineal Parenchymal Tumors Prog Neurol Surg. 2009;23:26-43.Tsumanuma I, Tanaka R, Fujii Y.Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan. 相似文献
12.
《中国神经肿瘤杂志》2012,(1):5+13+18+23+29+37+50+62+68-5
正Treatment-related change versus tumor recurrence in high-grade gliomas:a diagnosticconundrum-use of dynamic susceptibility contrast-enhanced(DSC) perfusion MRI.Am J Roentgenol.2012 Jan;198(1):19-26.Fatterpekar GM,Galheigo D,Narayana A,Johnson G,Knopp E. 相似文献
13.
《中国神经肿瘤杂志》2012,(2):116+133
Impact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome:A Meta-Analysis.J Clin Oncol.2012 Apr 23.[Epub ahead of print]De Witt Hamer PC,Gil Robles S,Zwinderman AH,Duffau H,Berger MS.Philip C.De Witt Hamer,Neurosurgical Center Amsterdam,Vrije Universiteit University Medical Center 相似文献
14.
《中国神经肿瘤杂志》2011,(1):6+20+38+56+60+65+74+76
Gamma knife stereotactic radiosurgery for the management of incidentally-identified brainmetastasis from non-small cell lung cancer.J Neurooncol.2011 Mar 23.[Epub ahead of print]Marko NF,Suh JH,Chao ST,Barnett GH,Vogelbaum MA,Toms S,Weil RJ,Angelov L.Department of Neurosurgery,Cleveland Clinic,Cleveland,OH,USA. 相似文献
15.
《中国神经肿瘤杂志》2012,(3):146+151+157+172+183+188+211+214
Temozolomide responsiveness in aggressive corticotroph tumours:a case report andreview of the literature Pituitary.2012 Sep;15(3):276-87.Annamalai AK,Dean AF,Kandasamy N,Kovacs K,Burton H,Halsall DJ,Shaw AS,Antoun NM,Cheow HK,Kirollos RW,Pickard JD,Simpson HL,Jefferies SJ,Burnet NG,Gurnell M. 相似文献
16.
《中国神经肿瘤杂志》2011,(2):81-81
Convexity meningiomas:study of recurrence factors with special emphasis on thecleavage plane in a series of 100 consecutive patients.J Neurosurg.2011 Jun 10.[Epub ahead of print]Alvernia JE,Dang ND,Sindou MP.Department of Neurosurgery,St.Edward Mercy Medical Center,Fort Smith,Arkansas 相似文献
17.
18.
目的:探讨survivin,TRAIL在正常脑组织和不同级别胶质瘤中的表达情况及其相关性。方法:收集脑外伤后内减压正常脑组织8例,胶质瘤组织40例,免疫组化方法检测survivin及TRAIL的表达情况。结果:Survivin,TRAIL蛋白在正常脑组织和胶质瘤组织中阳性表达率比较差异都有统计学意义(P<0.05)。Survivin在胶质瘤低级别组(I、II级)与高级别组(III、IV级)之间的阳性表达率比较差异有统计学意义(P<0.05)。TRAIL在胶质瘤低级别与高级别之间的阳性表达率比较差异没有统计学意义(P>0.05)。Spearman相关分析显示survivin表达强度与胶质瘤的恶性程度呈正相关(r=0.502,P<0.05)。Survivin蛋白和TRAIL蛋白在胶质瘤组织中的表达呈显著负相关(r=-0.553,P<0.05)。结论:胶质瘤细胞的增殖与凋亡可能与survivin和TRAIL的表达有关。 相似文献
19.
我院于1977~1988年收治恶性淋巴瘤164例,随访156例,1、3、5年存活率分别为57.1%、33.3%和28.8%,分析影响长期存活因素中,认为主要决定于治疗措施。以放、化疗结合并辅以中药、免疫治疗组的5年存活率最高,其5年存活率(45.4%)明显高于单纯放疗组(20.5%)及单纯化疗组(27.7%)。何杰金氏淋巴瘤(HD)5年存活率明显高于非何杰金氏淋巴瘤(NHL)。并认为综合治疗应以联合化疗为主,有计划地结合60C。放疗及其他治疗措施为宜。死亡的主要原因是局部复发和远处转移。 相似文献
20.
CT引导125I放射性粒子植入治疗复发性脑胶质瘤的研究 总被引:4,自引:0,他引:4
目的:探讨^125I放射粒子植入治疗复发性脑胶质瘤的技术方法、疗效和安全性。方法:33例手术或放疗后复发性脑胶质瘤患者行CT引导下^125I粒子植入术,根据术前计划确定粒子数目、空间分布和粒子针数目。粒子活度为0.4-0.8mCi,间距为0.5~1.0cm,共植入粒子10~35颗,术后即刻行CT扫描并进行质量验证。术后定期复查CT。结果:按照WHO疗效评价标准,1、3和6个月时有效率分别为48.5%、67.7%和80.0%。全组中位生存期16个月,其中1~2级胶质瘤中位生存期26个月,3~4级胶质瘤中位生存期11个月;全组1年生存率为66.7%(22/33),其中1~2级胶质瘤1年生存率为85.0%(17/20),3~4级胶质瘤1年生存率为38.5%(5/13)。并发症包括针道少量出血4例,局部脑坏死5例。未出现与治疗相关的死亡病例。结论:CT引导^125I粒子植入治疗复发性脑胶质瘤具有安全、微创、并发症少和疗效肯定等优点,值得进一步应用。 相似文献